Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Cε

Journal of Biological Chemistry

Volumn 287, Issue 35, 2012, Pages 29825-29836

  Aziz, Moammir H ^a   Shen, Hong ^a   Maki, Carl G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-APOPTOTIC FACTOR; BREAST CANCER CELLS; CASPASE-3; CIS-PLATIN; DEXAMETHASONES; GLUCOCORTICOID RECEPTOR; HUMAN MAMMARY EPITHELIAL CELLS; INDUCED APOPTOSIS; MAMMARY EPITHELIAL CELLS; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTECTIVE EFFECTS; PROTEIN KINASE C; PROTEIN LEVEL;

DRUG PRODUCTS; HORMONES; IONIZING RADIATION; PLATINUM COMPOUNDS; TRANSCRIPTION FACTORS;

CELL DEATH;

CASPASE 3; CASPASE 7; CISPLATIN; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MESSENGER RNA; MIFEPRISTONE; NUTLIN 3; PROTEIN KINASE C EPSILON; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL LEVEL; CELL PROTECTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; IONIZING RADIATION; MITOCHONDRIAL MEMBRANE POTENTIAL; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASE 7; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CISPLATIN; DEXAMETHASONE; ENZYME ACTIVATION; FEMALE; GAMMA RAYS; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROCORTISONE; PROTEIN KINASE C-EPSILON; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865461453     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.393256     Document Type: Article

References (54)

1. Zilfou, J. T., and Lowe, S. W. (2009) Tumor-suppressive functions of p53. Cold Spring Harbor Perspect. Biol. 1, 1-12
2. Chen, J., Marechal, V., and Levine, A. J. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13, 4107-4114
3. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. (1993) Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362, 857-860
4. Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z. G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., and Yuan, Z. M. (2011) The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 108, 12001-12006
5. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299
6. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997) Regulation of p53 stability by Mdm2. Nature 387, 299-303
7. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967
8. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-4300
9. Gasco, M., Shami, S., and Crook, T. (2002) The p53 pathway in breast cancer. Breast Cancer Res. 4, 70-76
10. Soussi, T. (2000) The p53 tumor suppressor gene. From molecular biology to clinical investigation. Ann. N.Y. Acad. Sci. 910, 121-137
11. Tennis, M., Krishnan, S., Bonner, M., Ambrosone, C. B., Vena, J. E., Moysich, K., Swede, H., McCann, S., Hall, P., Shields, P. G., and Freudenheim, J. L. (2006) p53 mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol. Biomark. Prev. 15, 80-85
12. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network. Nature 408, 307-310
13. Moll, U. M., Riou, G., and Levine, A. J. (1992) Two distinct mechanisms alter p53 in breast cancer. Mutation and nuclear exclusion. Proc. Natl. Acad. Sci. U.S.A. 89, 7262-7266
14. Bragado, P., Armesilla, A., Silva, A., and Porras, A. (2007) Apoptosis by cisplatin requires p53-mediated p38α MAPK activation through ROS generation. Apoptosis 12, 1733-1742
15. Impicciatore, G., Sancilio, S., Miscia, S., and Di Pietro, R. (2010) Nutlins and ionizing radiation in cancer therapy. Curr. Pharm. Des. 16, 1427-1442
16. Wu, G. S., and El-Deiry, W. S. (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin. Cancer Res. 2, 623-633
17. Wu, G. S., and Ding, Z. (2002) Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21, 1-8
18. Wu, W., Chaudhuri, S., Brickley, D. R., Pang, D., Karrison, T., and Conzen, S. D. (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 64, 1757-1764
19. Wu, W., Pew, T., Zou, M., Pang, D., and Conzen, S. D. (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J. Biol. Chem. 280, 4117-4124
20. Moran, T. J., Gray, S., Mikosz, C. A., and Conzen, S. D. (2000) The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 60, 867-872
21. Mikosz, C. A., Brickley, D. R., Sharkey, M. S., Moran, T. W., and Conzen, S. D. (2001) Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J. Biol. Chem. 276, 16649-16654
22. Pan, D., Kocherginsky, M., and Conzen, S. D. (2011) Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor- negative breast cancer. Cancer Res. 71, 6360-6370
23. Jonat, C., Rahmsdorf, H. J., Park, K. K., Cato, A. C., Gebel, S., Ponta, H., and Herrlich, P. (1990) Antitumor promotion and anti-inflammation. Downmodulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62, 1189-1204
24. Wyszomierski, S. L., Yeh, J., and Rosen, J. M. (1999) Glucocorticoid receptor/ signal transducer and activator of transcription 5 (STAT5) interactions enhance STAT5 activation by prolonging STAT5 DNA binding and tyrosine phosphorylation. Mol. Endocrinol. 13, 330-343
25. Brostjan, C., Anrather, J., Csizmadia, V., Stroka, D., Soares, M., Bach, F. H., and Winkler, H. (1996) Glucocorticoid-mediated repression of NFκB activity in endothelial cells does not involve induction of IκBα synthesis. J. Biol. Chem. 271, 19612-19616
26. Distelhorst, C. W. (2002) Recent insights into the mechanism of glucocorticosteroid- induced apoptosis. Cell Death Differ. 9, 6-19
27. Greenstein, S., Ghias, K., Krett, N. L., and Rosen, S. T. (2002) Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin. Cancer Res. 8, 1681-1694
28. Herr, I., Ucur, E., Herzer, K., Okouoyo, S., Ridder, R., Krammer, P. H., von Knebel Doeberitz, M., and Debatin, K. M. (2003) Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 63, 3112-3120
29. Pan, Q., Bao, L. W., Kleer, C. G., Sabel, M. S., Griffith, K. A., Teknos, T. N., and Merajver, S. D. (2005) Protein kinase Cε is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 65, 8366-8371
30. Aziz, M. H., Sundling, K. E., Dreckschmidt, N. E., and Verma, A. K. (2009) Protein kinase Cε inhibits UVR-induced expression of FADD, an adaptor protein, linked to both Fas- and TNFR1-mediated apoptosis. J. Invest. Dermatol. 129, 2011-2021
31. Aziz, M. H., Hafeez, B. B., Sand, J. M., Pierce, D. B., Aziz, S. W., Dreckschmidt, N. E., and Verma, A. K. (2010) Protein kinase Cvarε mediates Stat3Ser-727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 29, 3100-3109
32. Bourguignon, L. Y., Spevak, C. C., Wong, G., Xia, W., and Gilad, E. (2009) Hyaluronan-CD44 interaction with protein kinase Cε promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 284, 26533-26546
33. Dwivedi, Y., and Pandey, G. N. (1999) Administration of dexamethasone up-regulates protein kinase C activity and the expression of γ and κ protein kinase C isozymes in the rat brain. J. Neurochem. 72, 380-387
34. Maddali, K. K., Korzick, D. H., Turk, J. R., and Bowles, D. K. (2005) Isoform- specific modulation of coronary artery PKC by glucocorticoids. Vascul. Pharmacol. 42, 153-162
35. Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., Rao, M., Yu, P., Dominguez-Vidana, R., Liang, A. C., Solimini, N. L., Bernardi, R. J., Yu, B., Hsu, T., Golding, I., Luo, J., Osborne, C. K., Creighton, C. J., Hilsenbeck, S. G., Schiff, R., Shaw, C. A., Elledge, S. J., and Westbrook, T. F. (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335, 348-353
36. Hammond, S. L., Ham, R. G., and Stampfer, M. R. (1984) Serum-free growth of human mammary epithelial cells. Rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc. Natl. Acad. Sci., U.S.A. 81, 5435-5439
37. Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M. C. (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973-982
38. Ozes, O. N., Akca, H., Mayo, L. D., Gustin, J. A., Maehama, T., Dixon, J. E., and Donner, D. B. (2001) A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. U.S.A. 98, 4640-4645
39. Sengupta, S., Vonesch, J. L., Waltzinger, C., Zheng, H., and Wasylyk, B. (2000) Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J. 19, 6051-6064
40. Sengupta, S., and Wasylyk, B. (2001) Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev. 15, 2367-2380
41. Ní Chonghaile, T., Concannon, C. G., Szegezdi, E., Gorman, A. M., and Samali, A. (2006) Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. Apoptosis 11, 1247-1255
42. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848
43. Liu, W., Konduri, S. D., Bansal, S., Nayak, B. K., Rajasekaran, S. A., Karuppayil, S. M., Rajasekaran, A. K., and Das, G. M. (2006) Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function. J. Biol. Chem. 281, 9837-9840
44. Sayeed, A., Konduri, S. D., Liu, W., Bansal, S., Li, F., and Das, G. M. (2007) Estrogen receptor α inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 67, 7746-7755
45. Wallace, A. D., and Cidlowski, J. A. (2001) Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 276, 42714-42721
46. Webster, J. C., Jewell, C. M., Bodwell, J. E., Munck, A., Sar, M., and Cidlowski, J. A. (1997) Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 272, 9287-9293
47. Petiti, J. P., De Paul, A. L., Gutiérrez, S., Palmeri, C. M., Mukdsi, J. H., and Torres, A. I. (2008) Activation of PKCε induces lactotroph proliferation through ERK1/2 in response to phorbol ester. Mol. Cell. Endocrinol. 289, 77-84
48. Holden, N. S., Squires, P. E., Kaur, M., Bland, R., Jones, C. E., and Newton, R. (2008) Phorbol ester-stimulated NF-κB-dependent transcription. Roles for isoforms of novel protein kinase C. Cell. Signal. 20, 1338-1348
49. Gorin, M. A., and Pan, Q. (2009) Protein kinase Cε. An oncogene and emerging tumor biomarker. Mol. Cancer 8, 9
50. Baines, C. P., Zhang, J., Wang, G. W., Zheng, Y. T., Xiu, J. X., Cardwell, E. M., Bolli, R., and Ping, P. (2002) Mitochondrial PKCε and MAPK form signaling modules in the murine heart. Enhanced mitochondrial PKCε- MAPK interactions and differential MAPK activation in PKCε-induced cardioprotection. Circ. Res. 90, 390-397
51. Jabůrek, M., Costa, A. D., Burton, J. R., Costa, C. L., and Garlid, K. D. (2006) Mitochondrial PKC epsilon and mitochondrial ATP-sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ. Res. 99, 878-883
52. Cohen, M. V., Baines, C. P., and Downey, J. M. (2000) Ischemic preconditioning. From adenosine receptor to KATP channel. Annu. Rev. Physiol. 62, 79-109
53. Baines, C. P., Pass, J. M., and Ping, P. (2001) Protein kinases and kinasemodulated effectors in the late phase of ischemic preconditioning. Basic Res. Cardiol. 96, 207-218
54. Seoane, J., Le, H. V., and Massagué, J. (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734